| Identification | Back Directory | [Name]
ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT) | [CAS]
91421-87-3 | [Synonyms]
rANF 4-27
Auriculin A
ANP (4-27), RAT
AURICULIN A, RAT
ANP (126-149) (RAT)
atrialnatriureticfactor(8-33
Auriculin(R) A, rANF 4-27
ATRIAL NATRIURETIC PEPTIDE (126-149)
ATRIAL NATRIURETIC PEPTIDE (4-27), RAT
ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT)
atrial natriuretic peptide*fragment 4-27 rat
N-L-Arginylatrial natriuretic peptide-23 (rat)
Atrial natriureticpeptide-23 (rat), N-L-arginyl- (9CI)
Atrial Natriuretic Peptide, fragment4-27 from rat
H-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-ILE-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-OH
H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-OH, (Disulfide bond)
ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-ILE-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG(DISULFIDE BRIDGE:CYS4-CYS20)
ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-ILE-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG: RSSCFGGRIDRIGAQSGLGCNSFRDISULFIDE BRIDGE CYS7-CYS23 | [Molecular Formula]
C104H168N38O33S2 | [MDL Number]
MFCD00076238 | [MOL File]
91421-87-3.mol | [Molecular Weight]
2542.81 |
| Hazard Information | Back Directory | [Uses]
Auriculin A is a synthetic atrial?natriuretic?factor?(ANF) with hemodynamic effect. Auriculin A antagonizes renal vasoconstriction in the dog, and influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits[1][2]. | [in vivo]
Auriculin A (0.3 μg/min/kg; i.v.; for 30 min) antagonizes renal vasoconstriction in the dog[1].
Auriculin A (2 μg/kg prime, 0.2 μg/kg/min; i.v.; for 45 min) influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits[2].
| Animal Model: | Female mongrel dogs used in early clamp experiments (15-20 kg, anesthetized with 30 mg/kg pentobarbital sodium i.v.)[1] | | Dosage: | 0.3 μg/min/kg | | Administration: | Intravenous injection; last for 30 min | | Result: | Increased glomerular filtration rate (GFR) 16±4% and Na excretion (UNa V) 261±63%, whereas it decreased urine osmolality (Uosm) 36±7% without changing free water clearance.
Also increased diuresis (V) and kaliuresis (UKV). |
| Animal Model: | New Zealand white male rabbits (3-3.5 kg, anesthetized with 50 mg/kg Chloralose (HY-B1020) and 500 mg/kg Urethane (HY-B1207) i.v.)[2] | | Dosage: | 0.5 μg/kg prime, 0.05 μg/kg/min; 2 μg/kg prime, 0.2 μg/kg/min; 4 μg/kg prime, 0.4 μg/kg/min; 8 μg/kg prime, 0.8 μg/kg/min | | Administration: | Intravenous injection; last for 30-60 min | | Result: | Significantly reduced mean blood pressure and increased mean perfusion pressure at 4 μg/kg prime, 0.4 μg/kg/min dose, while heart rate did not change. |
| [References]
[1] Sosa RE, et al. Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. Am J Physiol. 1986 Mar;250(3 Pt 2):F520-4. DOI:10.1152/ajprenal.1986.250.3.F520
[2] Volpe M, et al. Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit. Circ Res. 1987 May;60(5):747-55. DOI:10.1161/01.res.60.5.747 |
|
| Company Name: |
cjbscvictory
|
| Telephone: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
|